ArticleJournal of cancer research and clinical oncology2023
Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 34 citations in OpenAlex.
- Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboringAnnals of medicine · 2026Article
- A thoracic SMARCA4-deficient undifferentiated tumor: A case report.Oncology letters · 2026Article
- ThoracicJournal of thoracic disease · 2026Article
- Wnt signaling-mediated activation of cancer cell stemness in thoracic SMARCA4-deficient undifferentiated tumor cells.Cell death discovery · 2026Article
- Bibliometric analysis and knowledge mapping of thoracic SMARCA4-deficient undifferentiated tumor.Discover oncology · 2026Article
- Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report.Translational lung cancer research · 2026Article
- PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report.Frontiers in immunology · 2026Article
- Case Report: Synaptophysin-positive SMARCA4-deficient undifferentiated thoracic tumour: a diagnostic pitfall with therapeutic implications.Frontiers in oncology · 2026Article
- Case Report: SMARCA4-deficient non-small cell lung cancer - effective local control with radiotherapy and emergence of a targetable EGFR mutation.Frontiers in oncology · 2026Article
- A case report of thoracic SMARCA4-deficient undifferentiated tumor associated with brain metastases.Frontiers in oncology · 2026Article
- Clinicopathological and molecular perspectives on thoracic SMARCA4-deficient undifferentiated tumors and SMARCA4-deficient non-small cell lung carcinomas.Pathologica · 2025Review
- Retrospective evaluation of anti-angiogenic and immune checkpoint inhibitor combination therapy in SMARCA4-deficient thoracic tumors: efficacy, safety, and biomarker considerations.Translational lung cancer research · 2025Article
- Potential efficacy of anti-angiogenic therapy combined with immunotherapy for advanced SMARCA4-deficient thoracic tumor: a retrospective study.Translational lung cancer research · 2025Article
- Transformation of Thoracic SMARCA4-Deficient Undifferentiated Tumour to Squamous Cell Carcinoma: A Case Report.Respirology case reports · 2025Article
- Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis.The oncologist · 2025Article
- Long-term survival of a SMARCA4-deficient undifferentiated thoracic tumor with brain metastasis successfully treated with multimodal treatment: a case report and literature review.Journal of cancer research and clinical oncology · 2025Review
- Review
- Successful treatment with sintilimab for SMARCA4-deficient non-small cell lung carcinoma: two case reports.Discover oncology · 2025Article
- Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches.The oncologist · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThoracic SMARCA4-deficient undifferentiated tumor (SD-UT) is a highly aggressive disease that is nosologically related to but distinct from SMARCA4-deficient non-small cell lung cancer (SD-NSCLC). No standard treatment guidelines were established for SD-UT. This research explored the efficacy of different treatments in SD-UT, and the prognostic, clinicopathologic and genomic difference between SD-UT and SD-NSCLC. MATERIALS AND
methodsInformation of 25 SD-UT and 22 SD-NSCLC patients diagnosed and treated in Fudan University Shanghai Cancer Center from January, 2017 to September, 2022 was analyzed.
resultsSD-UT was similar to SD-NSCLC in characteristics of onset age, male prevalence, heavy smoking history and metastatic pattern. SD-UT showed a rapid relapse pattern after radical therapy. For Stage IV SD-UT patients, immune checkpoint inhibitor (ICI) plus chemotherapy significantly improved median progression-free survival (PFS) compared to traditional chemotherapy as first-line treatment (26.8 vs. 2.73 months, p = 0.0437), while objective response rates of two arms were comparable (71.4% vs. 66.7%). No significant survival differences were observed between SD-UT and SD-NSCLC under similar treatment settings. SD-UT or SD-NSCLC patients receiving ICI in the first line had significantly prolonged OS than those with ICI in the latter lines or without ICI treatment throughout clinical courses. Genetic study found frequent SMARCA4, TP53 and LRP1B mutations in SD-UT.
conclusionTo the best of our knowledge, this is the largest series to date to compare the efficacy of ICI-based treatment to chemotherapy and document frequent mutations of LRP1B in SD-UT. ICI plus chemotherapy is an effective strategy for Stage IV SD-UT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.